Business Wire

The AgreenaCarbon Project Becomes the First Large-Scale Soil Carbon Project to Achieve Verra Verification, Now Issuing 2.3 Million Verified Carbon Credits

15.9.2025 10:30:00 CEST | Business Wire | Press Release

Share

Agreena, the company powering the global transition to regenerative agriculture, has achieved verification of its AgreenaCarbon Project under Verra’s Verified Carbon Standard (VCS) Program’s VM0042 Improved Agricultural Land Management v2.0 methodology – the first large-scale arable agriculture project to do so. By passing this milestone, Agreena is now issuing 2.3 million Verra-verified carbon credits that are not only readily available, but deliver immediate, measurable climate impact.

This follows the project’s successful validation in January 2025. While validation confirms that the project design and methodology meet the requirements of Verra’s VCS Program, verification is the critical next step - confirming, through independent assessment, that the project has delivered measurable climate outcomes as intended. Verra’s VCS Program is the world’s most widely recognised greenhouse gas crediting standard and is approved by the Integrity Council for the Voluntary Carbon Market.

Unlike other approaches, nature-based climate solutions deliver immediate impact. Operating across 1.6 million hectares of regenerative agriculture, the AgreenaCarbon Project and its carbon credits have enabled the reduction of 1.2 million tonnes of CO₂ and removal of 1.1 million tonnes of CO₂.

Mandy Rambharos, the Chief Executive Officer of Verra, commented: “The AgreenaCarbon Project is extremely important because it demonstrates how soil carbon projects can scale. It spans vast areas of land across multiple countries in Europe - from Ukraine to Spain - showing the breadth and reach of its impact. By implementing VM0042 and ensuring the right protocols, we can guarantee the quality and integrity of the carbon credits generated. This gives us confidence that these projects truly have the ability to scale.”

Simon Haldrup, CEO and co-founder of Agreena, added: “The verification of the AgreenaCarbon Project reaffirms Agreena as a leader in regenerative agriculture, proving that soil carbon sequestration can be measured, verified, and trusted at scale. This milestone empowers farmers – the true climate heroes – to adopt new practices through verified carbon credits, while giving corporate buyers the confidence to invest in meaningful climate action. Agreena is proud to be building the world’s largest verified supply of soil carbon credits, bringing the first large-scale wave of high-quality credits to market.”

Delivering immediate, scalable impact

Agreena’s impact is directly felt by farmers. As Oleksandr Mustipan, a farmer at Agrain Group of Companies, said: “Working with Agreena has truly been a game-changer. It enabled us to scale up regenerative practices more quickly and effectively than I ever could have alone. The Verra verification is another clear proof point of the seriousness and credibility of the AgreenaCarbon Project, built on the highest international standards. As a farmer, it’s motivating to know that the work we do contributes to real climate impact and is part of a larger, meaningful effort.”

The AgreenaCarbon Project, which has enrolled 1.6 million hectares of regeneratively farmed land, partners with farmers in the UK, Denmark, Ukraine, Moldova, Romania, Lithuania, Latvia, Estonia, Bulgaria, and Spain. By implementing regenerative practices that reduce and remove greenhouse gas emissions, farmers are delivering measurable climate impact and environmental benefits.

Now verified by Verra and an independent Validation/Verification Body (VVB), Agreena is able to issue Verified Carbon Units that meet the world’s most rigorous standards - ensuring the integrity of every credit that will follow. Several large European companies with sustainability targets, e.g. Radisson Hotel Group, have already pre-ordered a significant share of the credits, with issuance now opening up these credits to all companies looking for high-integrity, scalable nature-based solutions.

Agreena is now issuing the Project’s first VCUs, following the verification of vintage years 2021, 2022 and 2023.

Find out more here.

About Agreena

Headquartered in Denmark, Agreena is powering the global transition to regenerative agriculture, operating Europe’s leading soil carbon programme. Agreena collaborates with thousands of farmers across 4.5 million hectares of arable land in 20 markets.

Through its flagship AgreenaCarbon Project - the first large-scale agricultural cropland initiative verified under Verra’s world-renowned Verified Carbon Standard - Agreena supports farmers in adopting regenerative practices and generating high-integrity carbon credits.

Agreena finances farmers’ transition to sustainable practices, measures and verifies the climate impact with field-level accuracy, and offers climate solutions to corporates to achieve their sustainability goals. Uniquely, Agreena’s holistic solution combines proprietary digital measurement, reporting, and verification (dMRV) capabilities, leveraging AI and satellite imagery to unlock nature-based solutions at scale with ground-level accuracy.

Visit: www.agreena.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250915494673/en/

Contacts

Media contacts

International
Leah Jones
CommsCo
ljones@thecommsco.com
+44 7876 117760

Denmark
Peter Kjærgaard
peterkjaergaard0@gmail.com
+45 25 42 42 02

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye